The pharmaceutical industry is navigating one of its most significant operational transformations in decades. As the Drug Supply Chain Security Act (DSCSA) enforcement period matures, companies are discovering that compliance success hinges on details many initially overlooked—chief among them, how they identify and communicate location data across their trading partner networks.
Continue reading Mastering Location Identification: A Practical Guide to GLN Implementation for Pharma Supply Chains
There’s a federal regulation coming into full effect on November 27, 2026, that could impact how you run your medical practice, aesthetic clinic, or med spa. If you keep prescription medications on-site—whether for injections, procedures, or patient sales—you need to understand the Drug Supply Chain Security Act (DSCSA) and what it means for your day-to-day operations.
This isn’t about adding red tape. It’s about protecting patients from counterfeit and contaminated drugs. But it does mean new tracking requirements, and the clock is ticking.
Let’s walk through what you need to know and how to prepare without disrupting your practice.
Continue reading Is Your Medical Practice Ready for 2026? A Practical Guide to DSCSA ComplianceEssential Guidance for Pharmaceutical Companies Adapting to New Serialization Requirements
The pharmaceutical industry stands at a crossroads. Two major regulatory shifts are converging to reshape how drug products are identified, tracked, and verified throughout the distribution network. Understanding these changes and implementing compliant systems is no longer optional—it’s a fundamental requirement for market access.
The Drug Supply Chain Security Act’s enhanced traceability mandates have moved from planning phase to full operational reality. At the same time, the Food and Drug Administration is overhauling the National Drug Code structure, expanding it from its traditional format to accommodate future growth. These parallel transformations create both technical challenges and opportunities for companies willing to invest in robust identification infrastructure.
This article provides practical guidance for pharmaceutical manufacturers navigating this transition, with specific focus on how to properly construct Global Trade Item Numbers that meet both current compliance requirements and prepare for the expanded NDC format coming in the next several years.
Continue reading Navigating GTIN Standards for NDC Compliance: Your 2025-2026 RoadmapIowa lawmakers are tackling a $20 billion blind spot in pharmaceutical regulation—and the implications reach far beyond state borders.
When most people think about pharmaceutical regulation, they picture traditional pharmacies with their familiar orange prescription bottles and white-coated pharmacists. But there’s a massive segment of the healthcare industry dispensing prescription medications with virtually no oversight: medical spas and wellness clinics.
Iowa is about to change that equation dramatically.
Here’s a number that should get your attention: $5,000 to $20,000. That’s what most pharmaceutical organizations pay compliance consultants to develop a single DSCSA Standard Operating Procedure.
And that’s just the beginning. Add in 3-6 months of your team’s time, countless revision cycles, legal reviews, and the constant anxiety of wondering if you’ve covered everything the FDA expects to see.
Now imagine this scenario: FDA inspectors arrive at your facility for an unannounced inspection. Within the first hour, they ask to review your Drug Supply Chain Security Act procedures. You hand over what you have—maybe it’s outdated, maybe it’s incomplete, maybe it’s a patchwork of documents you’ve been meaning to organize.
DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of RxTrace. The material contained in RxTrace is not legal advice. The writers of RxTrace are not lawyers.
The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel
and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating
the positions of any company, organization or individual other than RxTrace.
RxTrace, a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance.
Contact Us | Privacy Statement
Copyright © 2009-2021 TrackTraceRx, Inc. All Rights Reserved.
RxTrace is a registered trademark of TrackTraceRx, Inc
